Relay Therapeutics Statistics Share Statistics Relay Therapeutics has 172.41M
shares outstanding. The number of shares has increased by 5.53%
in one year.
Shares Outstanding 172.41M Shares Change (YoY) 5.53% Shares Change (QoQ) 1.13% Owned by Institutions (%) 96.16% Shares Floating 130.15M Failed to Deliver (FTD) Shares 83,199 FTD / Avg. Volume 4.38%
Short Selling Information The latest short interest is 22.5M, so 13.05% of the outstanding
shares have been sold short.
Short Interest 22.5M Short % of Shares Out 13.05% Short % of Float 15.83% Short Ratio (days to cover) 15.01
Valuation Ratios The PE ratio is -1.74 and the forward
PE ratio is -2.47.
Relay Therapeutics's PEG ratio is
0.11.
PE Ratio -1.74 Forward PE -2.47 PS Ratio 58.82 Forward PS 88.6 PB Ratio 0.76 P/FCF Ratio -2.34 PEG Ratio 0.11
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Relay Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 15.95,
with a Debt / Equity ratio of 0.06.
Current Ratio 15.95 Quick Ratio 15.95 Debt / Equity 0.06 Debt / EBITDA -0.13 Debt / FCF -0.19 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $38.64K Profits Per Employee $-1.3M Employee Count 259 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -30.7% in the
last 52 weeks. The beta is 1.6, so Relay Therapeutics's
price volatility has been higher than the market average.
Beta 1.6 52-Week Price Change -30.7% 50-Day Moving Average 3.81 200-Day Moving Average 3.62 Relative Strength Index (RSI) 74.12 Average Volume (20 Days) 1,900,473
Income Statement In the last 12 months, Relay Therapeutics had revenue of 10.01M
and earned -337.71M
in profits. Earnings per share was -2.36.
Revenue 10.01M Gross Profit -305.43M Operating Income -372.47M Net Income -337.71M EBITDA -380.21M EBIT -385.67M Earnings Per Share (EPS) -2.36
Full Income Statement Balance Sheet The company has 124.29M in cash and 48.5M in
debt, giving a net cash position of 75.78M.
Cash & Cash Equivalents 124.29M Total Debt 48.5M Net Cash 75.78M Retained Earnings -1.74B Total Assets 728.84M Working Capital 647.87M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -249.11M
and capital expenditures -2.02M, giving a free cash flow of -251.13M.
Operating Cash Flow -249.11M Capital Expenditures -2.02M Free Cash Flow -251.13M FCF Per Share -1.76
Full Cash Flow Statement Margins Gross margin is -3052.2%, with operating and profit margins of -3722.07% and -3374.72%.
Gross Margin -3052.2% Operating Margin -3722.07% Pretax Margin -3374.72% Profit Margin -3374.72% EBITDA Margin -3799.44% EBIT Margin -3722.07% FCF Margin -2509.49%
